Targeted drugs

DRUG3 trials

Sponsors

Beijing 302 Hospital, Tianjin Medical University Cancer Institute and Hospital

Conditions

Acute LeukemiaHepatocellular CarcinomaImmune-related Adverse EventMalignant Solid TumorsSerum Ferritin

Early Phase 1

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

Not yet recruitingNCT06364800

Beijing 302 HospitalHepatocellular Carcinoma

Start: 2024-04-26End: 2026-09-26Target: 18Updated: 2024-04-15

Phase 1

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Not yet recruitingNCT06364787

Beijing 302 HospitalHepatocellular Carcinoma

Start: 2024-04-26End: 2026-09-26Target: 18Updated: 2024-04-15

Unknown Phase

The Effect of Serum Ferritin in irAE

RecruitingNCT06702566

Tianjin Medical University Cancer Institute and HospitalAcute Leukemia, Immune-related Adverse Event, Malignant Solid Tumors +1

Start: 2024-07-04End: 2027-07-01Target: 1500Updated: 2024-11-25